Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen

Frederik N Engsig; Jan Gerstoft; Gitte Kronborg; Carsten Schade Larsen; Gitte Pedersen; Anne M Audelin; Louise B Jørgensen; Niels Obel

Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen

Frederik N Engsig
, Jan Gerstoft
, Gitte Kronborg
, Carsten Schade Larsen
, Gitte Pedersen
, Anne M Audelin
, Louise B Jørgensen
, Niels Obel

Department of Infectious Diseases

4 Citations (Scopus)

Abstract

Raltegravir is the first integrase inhibitor approved for treatment of HIV-infected patients harboring multiresistant viruses.

Original language	English
Journal	Clinical Epidemiology
Volume	2
Pages (from-to)	145-51
Number of pages	7
ISSN	1179-1349
Publication status	Published - 1 Jan 2010

Cite this

@article{f4969369d11c4318bbe2d0a362d7bf88,

title = "Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen",

abstract = "Raltegravir is the first integrase inhibitor approved for treatment of HIV-infected patients harboring multiresistant viruses.",

author = "Engsig, \{Frederik N\} and Jan Gerstoft and Gitte Kronborg and Larsen, \{Carsten Schade\} and Gitte Pedersen and Audelin, \{Anne M\} and J{\o}rgensen, \{Louise B\} and Niels Obel",

year = "2010",

month = jan,

day = "1",

language = "English",

volume = "2",

pages = "145--51",

journal = "Clinical Epidemiology",

issn = "1179-1349",

publisher = "Dove Medical Press Ltd",

}

TY - JOUR

T1 - Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen

AU - Engsig, Frederik N

AU - Gerstoft, Jan

AU - Kronborg, Gitte

AU - Larsen, Carsten Schade

AU - Pedersen, Gitte

AU - Audelin, Anne M

AU - Jørgensen, Louise B

AU - Obel, Niels

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Raltegravir is the first integrase inhibitor approved for treatment of HIV-infected patients harboring multiresistant viruses.

AB - Raltegravir is the first integrase inhibitor approved for treatment of HIV-infected patients harboring multiresistant viruses.

M3 - Journal article

C2 - 20865112

SN - 1179-1349

VL - 2

SP - 145

EP - 151

JO - Clinical Epidemiology

JF - Clinical Epidemiology

ER -

Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen

Abstract

Fingerprint

Cite this